SCHEMBL4581124

SCHEMBL4581124

O=C(NN(C(=O)O)c1ccc(-c2ccc(CO)s2)cc1)c1ccc(-c2cccnc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.56
MKNK1 Q9BUB5 5/20 0.46
MKNK2 Q9HBH9 5/20 0.46
CYP2D6 P10635 4/20 0.44
CYP2C19 P33261 4/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2E1 P05181 2/20 0.44
CYP2B6 P20813 2/20 0.44
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581112 0.77 CYP2A6 (0.54) CYP2A6MKNK1MKNK2CYP2D6CYP2C19
SCHEMBL3611935 0.75 CYP2A6 (1.00) CYP2A6MKNK1MKNK2CYP2D6CYP2C19
SCHEMBL14155934 0.71 CYP2A6 (0.48) CYP2A6MKNK1MKNK2HDAC1NAMPT
SCHEMBL4753669 0.69 CYP2A6 (0.55) CYP2A6MKNK1MKNK2CYP2D6CYP2C19
SCHEMBL14526879 0.66 NPC1 (0.71) MKNK1MKNK2CYP2C9NPC1LMNA
SCHEMBL1109339 0.66 MKNK1 (0.73) MKNK1MKNK2HDAC3HDAC4HDAC1
SCHEMBL14082487 0.66 MKNK1 (0.64) MKNK1MKNK2NPC1LMNAGAA
SCHEMBL14082489 0.66 ALDH1A1 (0.61) MKNK1MKNK2HDAC3HDAC4HDAC1
SCHEMBL71397 0.65 CYP2A6 (0.65) CYP2A6CYP2D6CYP2C19CYP2C9CYP2E1
SCHEMBL12251213 0.65 MKNK1 (1.00) CYP2A6MKNK1MKNK2CYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 CYP2A6 4453/4885MKNK1 611/4885MKNK2 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.